# Gujarat Kidney And Super Speciality (NSE: GKSL) share price, financials and shareholding Source: https://app.pivotnow.in/stock/GKSL · Pivot · prices to 22 Oct 2026 Gujarat Kidney And Super Speciality (NSE: GKSL) closed at ₹183.00 on 22 Oct 2026, up 0.53% on the day. With a market capitalisation of ₹1,443 Cr, it ranks 1283rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities. At its last close the stock traded at 73.5× trailing earnings, against a return on equity of 36.3% in FY25. Its 52-week range is ₹98.36 (23 Jan 2026) to ₹209.80 (1 Oct 2026); the last close is 12.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹31 Cr (+212.7% year on year) and net profit ₹5 Cr (+263.2%), on a consolidated basis. Promoters held 71.45% of the company as of 30 Jun 2026. ## Key numbers | Metric | Value | | --- | --- | | Last close | ₹183.00 | | Market cap | ₹1,443 Cr | | P/E (trailing) | 73.5 | | ROE | 36.3% (FY25) | | ROCE | 39.9% (FY25) | | Debt to equity | 0.15 | | 52-week high | ₹209.80 (1 Oct 2026) | | 52-week low | ₹98.36 (23 Jan 2026) | ## Quarterly results (₹ crore, consolidated) | Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) | | --- | --- | --- | --- | --- | --- | | Q4 FY26 | ₹31 Cr | +212.7% | ₹5 Cr | +263.2% | ₹0.81 | | Q3 FY26 | ₹23 Cr | +97.2% | ₹4 Cr | +46.1% | ₹0.52 | | Q2 FY26 | ₹13 Cr | — | ₹3 Cr | — | ₹0.47 | | Q1 FY26 | ₹15 Cr | — | ₹5 Cr | — | ₹0.85 | | Q4 FY25 | ₹10 Cr | — | ₹1 Cr | — | ₹0.25 | | Q3 FY25 | ₹12 Cr | — | ₹3 Cr | — | ₹0.52 | ## Annual results (₹ crore) | Fiscal year | Revenue | Net profit | | --- | --- | --- | | FY25 | ₹40 Cr | ₹10 Cr | | FY24 | ₹5 Cr | ₹2 Cr | | FY23 | ₹0 Cr | −₹0 Cr | ## Shareholding (30 Jun 2026) - Promoters: 71.45% - Foreign institutions: 4.88% - Domestic institutions: 0.56% - Non-institutions: 23.10% ## Peers | Company | Price | Market cap | P/E | ROE | | --- | --- | --- | --- | --- | | [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹700.20 | ₹1,560 Cr | — | — | | [Suraksha Diagnostic](https://app.pivotnow.in/stock/SURAKSHA) | ₹294.05 | ₹1,531 Cr | 47.6 | — | | [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹496.20 | ₹1,435 Cr | 24.8 | — | | [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹216.03 | ₹1,422 Cr | 34.2 | — | | [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹994.70 | ₹1,406 Cr | 21.4 | — | | [Fermenta Biotech](https://app.pivotnow.in/stock/FERMENTA) | ₹466.35 | ₹1,373 Cr | — | — | ## Questions and answers ### What is the share price of Gujarat Kidney And Super Speciality today? Gujarat Kidney And Super Speciality (NSE: GKSL) last closed at ₹183.00 on 22 Oct 2026. Its 52-week high is ₹209.80 and its 52-week low is ₹98.36. ### What is the market cap of Gujarat Kidney And Super Speciality? Gujarat Kidney And Super Speciality's market capitalisation is ₹1,443 Cr (₹1,443 Cr) at the 22 Oct 2026 close, ranking 1283rd among the NSE companies Pivot tracks. ### What is the P/E ratio of Gujarat Kidney And Super Speciality? Gujarat Kidney And Super Speciality trades at a trailing P/E of 73.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.2. ### What is the ROE and ROCE of Gujarat Kidney And Super Speciality? Return on equity was 36.3% in FY25 and return on capital employed was 39.9% in FY25 (consolidated figures). ### Is Gujarat Kidney And Super Speciality a debt-free company? No. Gujarat Kidney And Super Speciality's debt-to-equity ratio was 0.15 in FY25, with total debt of ₹2 Cr. ### What were Gujarat Kidney And Super Speciality's latest quarterly results? For Q4 FY26 (quarter ended 31 Mar 2026), Gujarat Kidney And Super Speciality reported revenue of ₹31 Cr, +212.7% year on year, and net profit of ₹5 Cr, +263.2% year on year. ### What is the shareholding pattern of Gujarat Kidney And Super Speciality? As of 30 Jun 2026: promoters 71.45%, foreign institutions 4.88%, domestic institutions 0.56%, non-institutions 23.10%. ### Who are Gujarat Kidney And Super Speciality's competitors? The listed Pharma & Healthcare companies closest to Gujarat Kidney And Super Speciality by market cap are Astec LifeSciences, Suraksha Diagnostic, Amrutanjan Health Care, Jagsonpal Ser, TTK Healthcare and Fermenta Biotech. ### Is Gujarat Kidney And Super Speciality a good stock to buy? Pivot does not give buy or sell recommendations. This page sets out Gujarat Kidney And Super Speciality's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GKSL against its own history before risking money. This is analysis, not financial advice. --- Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.